World Health O. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021

Google Scholar 

Jindal A, Sarin SK. Hepatitis B: “Treat all” or “Treat select.” Hepatol Int. 2023;17(1):38–41

Article  PubMed  Google Scholar 

Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555

Article  PubMed  Google Scholar 

Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71(1):212–221

Article  PubMed  Google Scholar 

Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–238

Article  PubMed  PubMed Central  Google Scholar 

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–1761

Article  PubMed  Google Scholar 

D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–1193

Article  CAS  PubMed  Google Scholar 

European Association for the Study of the Liver. Electronic address and L European Association for the Study of the. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.

D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231

Article  PubMed  Google Scholar 

Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–335

Article  PubMed  Google Scholar 

Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91–100

Article  CAS  PubMed  Google Scholar 

JW Jang, JY Choi, YS Kim, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2018;16(12):1954–63 e3.

Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Dig Liver Dis. 2023;55(4):431–441

Article  PubMed  Google Scholar 

de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974

Article  PubMed  Google Scholar 

Wen S, Ruan J, Shen J, et al. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event. Scand J Gastroenterol. 2023:1–8.

Li M, Zong Z, Xiong X, et al. Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy. Front Cell Infect Microbiol. 2022;12:1053608

Article  CAS  PubMed  Google Scholar 

He Z, Zhou J, Tian Y, et al. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis. Scand J Gastroenterol. 2023;58(4):403–411

Article  PubMed  Google Scholar 

Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol. 2022;77(6):1564–1572

Article  CAS  PubMed  Google Scholar 

Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther. 2022;55(1):83–96

Article  CAS  PubMed  Google Scholar 

Balcar L, Tonon M, Semmler G, et al. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022;4(8): 100513

Article  PubMed  PubMed Central  Google Scholar 

Gupta A, Rana R, Agarwal S, et al. Assessing the risk of further decompensation and survival in patients with cirrhosis with variceal bleeding as their first decompensation event. Am J Gastroenterol. 2022. https://doi.org/10.14309/ajg.0000000000002018

Article  PubMed  PubMed Central  Google Scholar 

Xu XY, Ding HG, Li WG, et al. Chinese guidelines on the management of liver cirrhosis (abbreviated version). World J Gastroenterol. 2020;26(45):7088–7103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526

Article  PubMed  Google Scholar 

Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1): 32–6.

Giannini E, Botta F, Fumagalli A, et al. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients? Liver Int. 2004;24(5):465–470

Article  PubMed  Google Scholar 

Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19(2):105–115

Article  PubMed  PubMed Central  Google Scholar